Women with breast cancer who had lower perceptions of their cognitive abilities tended to have more anxiety or depression. Video games are fun, but can a new 'serious game' help women with breast or gynecologic cancer self-advocate? Battle and war metaphors are common in the cancer experience. But do they help or hurt? Reduced auditory function is common with taxane- and platinum-based treatments. Here's how you can help your patients. Though treatment has improved, outcomes have diverged since the mid-1980s. What can be done? Hormone replacement therapy is common, but is it safe? What are the risks of estrogen and progesterone therapy? The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial. Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate. Gene recurrence-score trial finds puzzling disparities in outcomes despite similarities in clinical factors. Nurse-led telephone-based consultations for adjuvant endocrine therapy may increase adherence. Improving access to evidence-based information for caregivers could improve outcomes for patients with breast cancer. Just 38% of patients with breast cancer receive at least 1 palliative care consult following metastatic disease diagnosis. All stakeholders have a role to play in increasing representation in this patient population. A study identified self-reported gaps from healthcare providers associated with providing treatment-related support. Research has shown that weight gain and obesity can be associated with an increased risk of developing breast cancer. Some research has shown that patients with certain autoimmune diseases have a lower risk of breast cancer. “CTCs contribute to the metastatic cascade and represent an independent survival predictor in breast cancer." Research has shown that women with breast cancer who live in socioeconomically disadvantaged areas have poorer outcomes. Breast cancer that is hormone receptor (HR)-positive tends to be diagnosed early, when it is highly treatable. The new research was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.